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ABSTRACT
Detection of genomic copy number changes has
10 been an important research area, especially in
cancer. Several high-throughput technologies have
been developed to detect these changes. Features
that are important for the utility of technologies
assessing copy number changes include the ability
15 to interrogate regions of interest at the desired dens-
ity as well as the ability to differentiate the two homo-
logs. In addition, assessing formaldehyde fixed and
paraffin embedded (FFPE) samples allows the utiliza-
tionofthevastmajorityofcancersamples.Toaddress
20 these points we demonstrate the use of molecular
inversion probe (MIP) technology to the study of
copy number. MIP is a high-throughput genotyping
technology capable of interrogating .20000 single
nucleotide polymorphisms in the same tube. We
25 have shown the ability of MIP at this multiplex level
to provide copy number measurements while obtain-
ingthealleleinformation. Inadditionwehavedemon-
strated a proof of principle for copy number analysis
in FFPE samples.
30 INTRODUCTION
DNA copy number changes occur in human disease and par-
ticularly in cancer. These changes include polyploidy, dele-
tions and ampliﬁcations. In addition there are changes leading
to loss of heterozygosity (LOH) without any copy number
35 change. The identiﬁcation of these changes may elucidate
targets for drug treatment, shed light on the process of tumor
progression and deﬁne markers that can predict the patient
prognosis and pharmaceutical response (1,2). Since the devel-
opment of comparative genomic hybridization (CGH) (3)
40 many technologies have been developed to date to address this
need. These include bacterial artiﬁcial chromosome (BAC)
CGH (4), cDNA CGH (5) and digital karyotyping (6). BAC
CGH is the most commonly used technique because it has a
superiorresolutionand/orsensitivitywhencomparedwiththese
45 other techniques (7). More recently CGH employing several
types of oligonucleotide arrays (8–12) has been described.
Some of these technologies have been scaled to assess the
genome using tens of thousands of loci (8–13). In addition to
the scalability, other features are important for a technology
50 assessing copy number in cancer. These include sensitivity
to detect single copy number changes, customization to assess
important regions the genome, preservation of allele informa-
tion and the ability to test samples that have been formalde-
hyde ﬁxed and parafﬁn embedded (FFPE). These four features
55 are present in various degrees in the different platforms, but
are not fully satisﬁed by any one platform. To address these
needs we apply the molecular inversion probes (MIP) tech-
nology to copy number analysis.
MIP probes have two speciﬁc homology sequences that
60 leave a 1 bp gap when hybridized to the genome (14,15).
They also contain speciﬁc tag sequences that are ultimately
read on the microarray. In addition to these elements that are
speciﬁc to each probe, there are two PCR primers that are
common to all probes. These primers face away from each
65 other and therefore cannot facilitate the ampliﬁcation. After
the probes are hybridized the reaction is split into four tubes
with 1 of the 4 nt added to each tube. With the gap ﬁlled in the
presence of the appropriate nucleotide a unimolecular ligation
event is catalyzed. After eliminating the linear probes with
70 exonucleases, PCRs using the common primers that now face
each other is performed in the four tubes. In addition to signal
ampliﬁcation a ﬂuorescent label is introducedby a PCRprimer
ineach ofthe four tubes.The four reactions are then mixed and
hybridized onto a tag array. As many as 22000 single nucle-
75 otide polymorphism (SNP) markers from an individual sample
can be interrogated. The MIP technology has several features
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doi:10.1093/nar/gni177that convey advantages for this application over other methods
using oligonucleotide arrays. In the assay, a high degree of
speciﬁcity is achieved through a combination of the unique
unimolecular probe design and selective enzymology which
5 also allows the technology to be very highly multiplexed. The
tag based read-out array also conveys distinct advantages. By
getting away from the use of genomic sequences to separate
the signals on the array, cross hybridization levels among the
different probes can be kept at a very low level allowing the
10 quantitative signals to be collected with high precision. Herein
this study we demonstrate these advantages and show the
utility of MIP for the detection of genomic aberrations. Fur-
thermore, we demonstrate the value of allele information and
provide a proof of principle for the use of this technology to
15 assess copy number in FFPE samples. These features and the
customizability of the MIP probes provide important advant-
ages for this technology.
METHODS
Samples and MIP assay
20 All the 44 reference cell lines were obtained from Coriell
Cell Repository (Camden, NJ). The samples had the following
names: NA18995, NA18621, NA18987, NA18990, NA18991,
NA18594, NA18573, NA18623, NA18981, NA18974,
NA18582, NA18633, NA18994, NA12234, NA10847,
25 NA10861, NA07345, NA12156, NA10863, NA12239,
NA10831, NA06991, NA11840, NA07056, NA12802,
NA12813, NA11830, NA19201, NA19193, NA19204,
NA19143, NA18523, NA19094, NA18870, NA19140,
NA18517, NA19221, NA19102, NA19100, NA18855,
30 NA19209 and NA19172. NA12156 was run in duplicate. In
addition we obtained the following test samples from Coriell:
GM1201, NA04626, NA01416, GM6061, HCC1937 BL
CRL2337 and HCC1937 CRL2336. The cell lines
HCC1395, UACC812, A2058 and MDA-MB-175-VII were
35 obtained from American Tissue Cell Culture (ATCC). To
minimize potential differences in DNA preparation, DNA
samples were subjected to a DNA puriﬁcation using Puregene
kit (Gentra, Minneapolis) as recommended by the manufac-
turer. The PPFE samples were obtained from Cooperative
40 Human Tissue Network (http://faculty.virginia.edu/chtn-tma/
home.html), aged from 1 to 3 years old, and they were puriﬁed
by Puregene kit (Gentra, Minneapolis) except the brain
sample which was puriﬁed with phenol-chloroform procedure.
Brieﬂy,several10mmsectionswerexylenetreated afewtimes
45 to dissolve parafﬁn, then subjected to ethanol washes. The
deparafﬁned and air-dried tissues were proteinase K treated
at 400 mg/ml in 0.5% SDS TE buffer at 55 C with vigorous
shaking overnight. The digested samples were then RNase A
treated for 1 h at 37 C, phenol-chloroform extracted and then
50 ethanol precipitated. The MIP assay on all samples was per-
formed as described previously (15).
DATA ANALYSIS
Copy sum and copy contrast computation
Signal from each chip is background subtracted, color
55 separated, normalized and genotypes called as described
previously (16). Using the reference samples the average
signal in each of the three clusters (two homozygous clusters
and a heterozygous cluster) for each marker as well as the
standard deviation of the signal after removing (15%) outliers
60 are calculated. The outlier rejection only applies for cal-
culating average properties of the marker. Later copy
number is estimated for all markers in all samples. The
average signal in a cluster is then set to denote two copies
since most reference samples will be diploid at any given
65 point in the genome. For homozygous clusters we only
consider the signal in the relevant allele and ignore the
signal in the other allele for the computation of copy number.
For heterozygous clusters we consider both signals and ana-
lyze them in two (orthogonal) directions: summing them
70 together (copy sum analysis) and taking their ratio (allele
ratio analysis). If a marker in a test sample has an allele
imbalance, it may be classiﬁed as homozygous and therefore
the signal inthe otherallele ignored. Inourdatawedetermined
that on average the misclassiﬁcation occurs when the two
75 alleles are present at a ratio of 7.7:1. Therefore ignoring a
real signal in one allele only occurs at extreme allele imbal-
ance ultimately making a small difference in the copy number
calculation.
Copy sum analysis is a way of measuring total copy number
80 irrespective ofalleleratio, hence it is‘hypothesisfree’interms
of allelic composition. For each allele, we perform a straight
line ﬁt (using linear regression) of the reference sample signals
against their genotype cluster membership assuming that the
clustersrepresent0,1and2copies(SupplementaryFigureS1).
85 This provides us with a background signal (Y-intercept) and
signal per copy (slope) for each allele so that any signal level
for any given allele of any marker in any sample can be
mapped to a copy number of that allele. Summing the inferred
copy numbers over both alleles gives us the ‘copy sum’ which
90 is equal to 2, on average (by construction), for the reference
samples. Supplementary Figure S2A shows that sum signal
(S1 + S2) has a slight dependence on genotype, for a parti-
cular example probe, as one of the two alleles produces more
signal than the other for this probe. However, copy sum has,
95 in general, no dependence on genotype (Supplementary
Figure S2B) since we have calibrated the signals in each allele
using the linear regressions shown in Supplementary Figure
S1. The relative standard deviation of copy sum (across the
reference samples) is a good measure of the reproducibility of
100 the copy sum measurement for any given marker. In addition
the number of standard deviations of a data point away from
the mean provides a conﬁdence score that this point represents
a deletion or ampliﬁcation. Supplementary Figure S2 also
shows that signal contrast, (S1   S2)/(S1 + S2), is not
105 equal to 0 for heterozygotes for this particular probe, again
because of the slight bias in signal between the two alleles for
the given example probe. For each probe we have corrected for
this potential bias by calculating copy contrast, effectively
(C1   C2)/(C1 + C2), where we normalize the signal contrast
110 measurement so that the average copy contrast of the hetero-
zygous reference samples is set to 0, as seen in Supplementary
Figure S2B. We also compute the standard deviation of the
copy contrast. The number of standard deviations of a data
point away from the mean copy contrast provides a conﬁdence
115 score that the speciﬁc point represents an allele ratio distinct
from 1:1.
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Allele ratio is derived from copy contrast and is given by the
smaller of C1/C2 and C2/C1 (with a proviso explained below).
Its main function is to provide a ratio metric that is amenable
5 to smoothing across neighboring markers. Since we have nor-
malized copy contrast so that it is equal to 0, on average, for
heterozygous reference samples, then the average allele ratio
of the heterozygous reference samples will be 1. In addition to
this normalization we have ‘symmetrized’ allele ratio so that it
10 is conﬁned to the interval 0–1, i.e. we always make the less
abundant allele appear on the numerator and the more abund-
ant allele on the denominator. This assignation of less/more
abundant alleles is done for each sample and can ﬂip back and
forth between samples for the same given marker. This is
15 necessary in order to allow for smoothing of allele ratio
data across neighboring markers, otherwise the non-1 allele
ratios would average to 1 (across a large number of markers)
and allele ratio information would be lost in smoothing. Since
we always calculate the ratio of the less to the more abundant
20 alleles, random measurement ﬂuctuation of the allele ratio for
heterozygous calls generates an allele ratio <1. To obtain an
allele ratio closer to 1 for the heterozygous calls we did not
enforce the rule of computing the ratio of the less to the more
abundant allele when the allele ratio of a speciﬁc sample was
25 within 1SDfrom the average forthe particularmarker.Instead
in these cases, the numerator and the denominator were
determined by the alphabetical order of the two alleles.
This correction explains why some of the computed allele
ratios are >1. Even with this correction, the allele ratio of
30 heterozygous calls is on average <1.
Sample normalization
Each sample has a single normalization constant that is used to
multiply all its measured signals before comparing it against
other samples. Initially, this constant is set so that each sample
35 has the same average (log) signal across all its markers. We
then perform the copy sum analysis and use all markers with
copy sum relative SD <0.2 to adjust the sample normalization
constant so that each sample has a median copy number of 2
for these markers (after allowing for 15% outliers). The outlier
40 rejection is done only for the purposes of sample normaliza-
tion. Later copy sum and allele ratio is computed for all
markers in all samples except for those that correspond to
blemished features on the chip (<1% of the data). In most
cases the adjustment factor is <10% showing that our original
45 normalization constant was well chosen. We iteratively repeat
the process of performing a copy sum analysis and adjusting
sample normalizations. After three iterations the normaliza-
tion factors have converged within 0.1% and so no further
iterations are needed. This automated sample normalization
50 procedure works well with samples that are mostly diploid
(with some chromosome abnormalities not exceeding 20–30%
of the genome). However, in the case of highly mutated cancer
cell lines where the diploid nature is completely overtaken
by chromosome abnormalities we have overridden the above
55 automated normalization procedure with a manual sample
normalization procedure. In these cases the sample normal-
ization factor was used as to set mode to equal 2. Clearly this is
still an invalid assumption and a better normalization may be
to identify the chromosome region with the smallest copy
60 number that is also consistent with allele ratio ¼ 1. This is
a most probable diploid region and can be used to manually
adjust this sample’s normalization constant so that this
region’s average copy number is equal to 2.
Data smoothing
65 For both copy number and allele ratio analyses we have
developed two algorithms for smoothing across neighboring
markers. In the ﬁrst method, a ﬁxed number of neighbors are
considered on each side of the current marker. In the second
method, neighbors are considered out to a ﬁxed distance and
70 are weighted according to a Gaussian function dependent on
this distance (Gaussian kernel smoothing). In both methods we
also apply, to each marker, a weight proportional tothe inverse
square of the relative standard deviation of the marker’s copy
sum (or allele ratio) as determined by the reference samples.
75 In this way we weight the markers according to how ‘reliable’
they are. Hence the smoothed data are less sensitive to poorly
performing markers. In addition, we allow outlier rejection for
a data point that is inconsistent with its neighbors.
Restriction fragment length polymorphism (RFLP)
80 To conﬁrm the allele ratio abnormality in a region on chro-
mosome 15 in the sample NA18573, we picked six SNPs that
create a RFLP and are heterozygous in this sample. PCR
primers amplifying  200 bp centered around the SNP were
designed. PCRs using genomic DNA from NA18573 and six
85 other control samples (1–3 were heterozygous for the speciﬁc
SNPs of interest) as template followed by restriction digests
were performed. Quantiﬁcation of the heterozygous bands
on 4% agorose gels was performed on Typhoon Imager
(Amersham Biosciences). The allele ratio was computed
90 using the ratio of the cut/uncut band in NA18573 after nor-
malization using the other three control samples.
Quantitative real-time PCR
In addition to Taqman, we performed real-time PCR using
SYBR green. Experiments were performed on Opticon DNA
95 Engine (MJ Research). Beta-actin Taqman Control reagent,
Taqman Universal PCR Master Mix and SYBR Green PCR
Master Mix were purchased from Applied Biosystems (Foster
City, CA). Additional Taqman dual labeled probes were
ordered from Ryss Lab Inc. (Union City, CA). Oligos not
100 used in Taqman were ordered from Intergrated DNA Tech-
nologies (Iowa, USA).
Real-time PCR conditions were 95 C for 10 min, 40 cycles
at 95 C for 15 s, 60 C for 1 min for Taqman; 95 C for 10 min,
40 cycles at 95 C for 20 s, 60 C for 20 s, 72 C for 20 s for
105 SYBR Green.Quantiﬁcationwas calculatedusingthe standard
curve method. Of the same primer set 2–40 repeats were per-
formed on the investigated DNA samples. The results were
plotted against the standard curve to obtain copy number
estimation.
110 RESULTS
Allele copy number determination by MIP
We wanted to assess the ability of MIP to measure allele copy
number. While these probes could be used to target any unique
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allows allelic information to be studied in addition to copy
number. We utilized a panel of 21904 SNPs in genic regions
across the genome. Genic regions encompassed the exons
5 and introns of genes as well as 5 kb on both sides of the
start and stop of the transcript. Using this gene deﬁnition
and the Ensembl database genes (http://www.ensembl.org/),
genic regions constitute about one-third of the genome.
Choosing SNPs in only the genic regions offered the ability
10 to obtain higher density in these higher priority genomic seg-
ments. To make the panel maximally informative, highly
polymorphic SNPs were chosen from the public databases.
In addition we ﬁltered out SNPs where the probe sequence
( 40 bp) was not unique in the genome or had another SNP.
15 The average separation between markers is  130 kb, and the
median is 52 kb. The big difference between the median and
the average reﬂects in part the large non-genic regions in the
genome.
Using this probe panel we performed the standard MIP
20 assay on 44 normal ‘reference’ samples (43 individuals) as
well as 10 ‘test’ samples (Table 1). The reference set we used
was lymphoblastoid cell lines utilized in the HapMap project
and representing different ethnic groups (17).
To determine copy number and the allele ratio at each locus
25 we performed the analysis described in the Methods section.
Brieﬂy, the ﬁrst step in the analysis was to study the reference
samples. We ﬁrst ran our genotype-calling algorithm on all the
reference samples to generate genotype calls for each sample.
The genotypes are called by clustering in the single dimension
30 of the contrast between the two allele signals (15,16). For each
of the twoalleles we estimate the average signal obtained from
one copy in the reference set. Signal intensity obtained for an
allele in a marker of a test sample is converted to copy number
by comparing with the value computed from the reference set.
35 Similarly allele ratio of the heterozygous samples in the ref-
erence samples is set to 1:1 and is used to estimate the ratio in
test samples.
In addition to the basic analysis for copy number and allele
ratio at every SNP, we utilized data from the surrounding
40 SNPs for ‘smoothing’ as described in the Methods section.
The smoothed results are more precise but have lower resolu-
tion than single marker data.
Quantitative performance
Out of 21904 SNP markers in the panel, 18180 passed our
45 genotyping performance criteria. For each of these markers we
Table 1. Samples utilized in the study
Sample Characteristic
GM1201 Monosomy 21
NA04626 3· cell line
NA01416 4· cell line
GM6061 5· cell line
HCC1937 BL CRL2337 Normal cell line
a
HCC1937 CRL2336 Tumor cell line
a
HCC1395 Cancer cell line
UACC812 Cancer cell line
A2058 Cancer cell line
MDA-MB-175-VII Cancer cell line
Brain tissue FFPE normal
Colon tissue FFPE normal
Liver tissue FFPE normal
Liver tissue FFPE normal
b
Liver tumor tissue FFPE tumor
b
These are the samples utilized in the study in addition to 44 (43 individuals)
normal cell line samples that are listed in the Methods section.
aThese are matched cell line pair.
bThese are matched tumor/normal pair.
Figure 1.RelationshipbetweencopysumRSDandsignalstrength.ForeachmarkercopysumRSDandtheaveragesignalstrengtharecalculatedusingthereference
samples as described in the Methods section.The best performingmarkersare thosewiththe lowestcopy sum RSD.As expected,markerswith low signal are more
probable to have higher copy sum RSD.
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sum RSD) in the 44 reference sample set (Supplementary
Table S1) as described in the Methods section. Copy sum
RSD utilizes data from all three genotype clusters to provide
5 a single measure describing the quality of a marker. All 18180
markers can provide some quantitative data, but markers with
the lowest copy sum RSD provided higher informativeness as
we show below. We noted that markers with weak signals tend
to have higher copy sum RSD (Figure 1).
10 Since we utilize genotype data in the reference set to cal-
ibrate copy number estimation, we assessed the dependence of
the precision of copy number determination on the number of
observations in the reference set. Eight samples were taken out
of the reference set and used as test samples to measure their
15 copy number. The precision of the copy number estimation
was then plotted as a function of the number of the hetero-
zygous calls in the reference set. As shown in Supplementary
Figure S3, the precision in copy number estimation is reason-
able even with one observation in the reference set and it
20 improves as the number of observation increases to  4.
False positive and negative rates
We assessed the performance of a single marker in detecting
single copy changes. For each call in every sample we obtain
the copy number and a signiﬁcance score derived from how
25 many standard deviations the measured copy number is away
from the mean of 2. The score that is considered ‘positive’ is
somewhat arbitrary and at different cut-off values the number
of false positives and negatives varies. To measure the accur-
acy rate we treated the reference set as ‘test’ and generated
30 quantitative data on all 44 reference samples (43 individuals).
We assumed that copy number measurements signiﬁcantly
lower from 2 in any of the autosomes are false positives
Figure 2. The trade-off between false positive and false negatives rates. The
false negative rate was computed using X chromosome markers in the males,
and the false positive rate was calculated using all the autosomes in the total
reference sample set. The effect of selecting different sets of markers based
on copy sum RSD is shown. The best markers (10101 probes) are plotted in
blue, all markers unfiltered are plotted in yellow (18180 probes) and an inter-
mediate cut is shown in pink (14342 probes).
Figure 3. Exampleresultsfromamalesample.Agenomiccopynumberviewofamalesample.Eachchromosomeislabeledandcodedwithauniquecolor.Inboth
panelsthe X-axis shows the best 10101 markersin the genomicorder.The Y-axis shows the copy number(upperpanel)and smoothedcopy numberusinga moving
windowofsevenmarkers(lowerpanel).Thecopynumberofmarkersontheautosomesfluctuatesaround2,distinctlydifferentfrommarkersontheXchromosome
(the last chromosome marked with an arrow). As expected the fluctuation is greatly reduced with the smoothing done by surrounding markers.
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of these signals was very low consistent with the fact that the
majority ofthese positives resulted fromassaynoise).Weused
data from the X chromosomes of the eight males in the ref-
5 erence set to measure the false negative rate in detecting single
copy deletions. We computed the false positive and negative
rates at different signiﬁcance cut-off values to assess how they
trade off against each other. In addition we calculated these
metrics for different sets of markers with different thresholds
10 of copy sum RSD values (Figure 2). As anticipated markers
with lower copy sum RSD are better in identifying single copy
changes. Unless otherwise indicated, the data presented below
are from the best 10101 markers.
One approach to improve the false positive and negative
15 rates is to ‘smooth’ the data utilizing information from
neighboring markers trading resolution for sensitivity.
Figure 3 shows example of the raw and smoothed data gen-
erated from one of the male samples.
Accuracy in copy number estimation
20 The average copy number for X markers in the males is 1.14,
and the average copy number for chromosome 21 markers in a
cell line with monosomy chromosome 21 is 1.22. Similarly,
the average copy number for X markers is 2.75, 3.22 and
3.60 in cell line with 3, 4 and 5 X chromosomes. This non-
25 linear effect has been observed previously with other techno-
logies assessing copy number on arrays (4), and it is worse
as the copy number increases (10). In our description of
results from cancer cell lines below, we assess the precision
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This is not surprising given that we know that the ﬂuorescent
signal response curve of array features is not linear when
products are present at high concentrations owing to feature
5 saturation.
Allele ratio
In addition to the copy number information we obtain
allele ratio information for each marker in every sample.
As a demonstration for the allele ratio we tested cell lines
C
D
Figure4.AlleleratioinpolysomyXcelllines.(A)AwholegenomeviewofthealleleratioinNA04626celllinewith3Xchromosomes.Eachchromosomeislabeled
and coded with a unique color. The X-axis shows the 10101 markers in the genomic order. The Y-axis shows the smoothed allele ratio. Points that are closest to the
homozygous cluster are assigned an allele ratio of 0 and those near the heterozygous cluster are smoothed using data from the non-homozygous markers within the
7markermovingwindow.Normalheterozygouscallsareexpectedtohaveanalleleratioof1,butourmeasurementsgeneratealoweralleleratioforreasonsexplained
in the method section. As expected for this cell line carrying three times the allele ratio for the X chromosome is 0.5 (arrow pointing to 1:2 ratio of 0.5) and for the
autosomesiscloseto1.(B)ThefalsenegativeratewascomputedusingXchromosomemarkersinthecelllinecontaining3Xchromosomes,andthefalsepositiverate
wascalculatedusingalltheautosomesinthissampleandthereferenceset.TheeffectofselectingdifferentsetsofmarkersbasedoncopysumRSDisshown.Thebest
markers (10101 probes) are plotted in blue, all markers unfiltered are plotted in yellow (18180 probes) and an intermediate cut is shown in pink (14342 probes).
(C)AlleleratiointheXchromosomeofNA01416celllinecontaining4Xchromosomes.TheX-axisshowschromosomeXpositionandtheY-axisdepictstheallele
ratio.Markerswithanalleleratioaround0arehomozygous.Inadditionanumberofmarkershaveanalleleratiocloseto1,andothershaveanalleleratioof0.33.The
shaded zones depict the regions with the expected allele ratio. (D) Allele ratio in the X chromosome of GM6061 cell line containing 5X chromosomes. The X-axis
showschromosomeXpositionandtheY-axisdepictsthealleleratio.Markerswithanalleleratioaround0arehomozygous.Inadditionanumberofmarkershavean
allele ratio close to 0.67, and others have an allele ratio around 0.25. The shaded zones depict the regions with the expected allele ratio.
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mosomes for the cell line containing three copies of the X
chromosomes are expected to have one allele at half the con-
centration of the other (i.e. allele ratio of 0.5). The average
5 measured allele ratio in this cell line was 0.48 indicating that
allele ratio estimation does not have the same non-linear beha-
vior as seen with copy number (Figure 4A). The performance
of markers in detecting the aberrant (i.e. not 1:1) allele ratio in
this cell line is shownin Figure 4B. We note that the difference
10 in performance between the best and all marker sets is smaller
than that seen in Figure 2 for copy number. This is because the
choice of the best markers is based on copy sum and not an
allele ratio measurement.
The origin of cells with polysomy X has been attributed
15 previously to non-disjunction in the two meiotic events in one
parent (18,19). Therefore the X chromosomes in the 4· and 5·
Figure5.Mosaicaberrationsinreferencesamples.(A)AgenomiccopynumberandalleleratioviewofthereferencesampleNA19193carryingamosaicduplication
ofchromosome12.Eachchromosomeislabeledandcodedwithauniquecolor.InbothpanelstheX-axisshowsthegenomicorderofthechromosomes11–13markers
thatbelongto thebest 10101markerset. TheY-axisusesa movingwindowofsevenmarkerstoshowthe smoothedcopynumber(upperpanel)andsmoothedallele
ratio(lowerpanel).Markersonchromosome12haveonaverageahighercopynumberandaloweralleleratiothanthesurroundingchromosomes.Thisisconsistent
witha‘mosaic’duplicationofchromosome12inafractionofthecells.(B)AgenomiccopynumberandalleleratioviewofthereferencesampleNA18573containing
amosaicLOHinchromosome15.Eachchromosomeislabeledandcodedwithauniquecolor.InbothpanelstheX-axisshowsthemarkersinthegenomicorderforall
chromosomes. The Y-axis uses a moving window of seven markers to show the smoothed copy number (upper panel) and smoothed allele ratio (lower panel). The
regioninchromosome15denotedbyanarrowhavethenormalcopynumberof2(upperpanel)butanalleleratioof0.6(lowerpanel).Thisisconsistentwithanevent
(e.g. mitotic recombination) leading some of the cells to have LOH with no change in copy number.
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allele ratio for a non-homozygous SNP on the X chromosome
in a 4· cell line is expected to be either 1 (two copies of each
allele) or 0.33 (one copy of one allele and three of the other)
5 depending on which of the three ‘parental’ chromosomes carry
the same allele for the SNP. Similarly the allele ratio for a non-
homozygous SNP on the X chromosome in a 5· cell line is
expected to be either 0.25 (one copy of one allele and four
of the other) or 0.67 (two copies of one allele and three of the
10 other). Our measured allele ratio is consistent with these
expectations (Figure 4C and D).
Abnormalities in the reference samples
Several ‘mosaic’ abnormalities with less than one copy num-
ber change were identiﬁed in the reference set. These changes
15 mayrepresentinvitro artifacts duringtheimmortalizationand/
or growth of the cell line. One of the abnormalities encom-
passed all of chromosome 12 (Figure 5A). The average allele
ratio in chromosome 12 for this sample was 0.7 instead of 0.5
expected from the presence of three copies, consistent with the
20 mosaic nature of the duplication. The mosaic nature of this
abnormality was conﬁrmed using Taqman (Table 2). Another
‘mosaic’ abnormality was a deletion smaller than 2 Mb on
chromosome 1.
Utilizing allele information we have also seen evidence of
25 ‘mosaic’ allele imbalance over a large genomic segment. This
is manifested by a normal copy number of 2 but an aberrant
allele ratio. Speciﬁcally instead of allele ratio  1, SNPs in
 99 Mb on chromosome 2 in the sample NA18855 and
 35 Mb on chromosome 15 in the sample NA18573 had allele
30 ratio of 0.69 and 0.6, respectively (Figure 5B). This is a prob-
able result of mitotic recombination or other mechanisms
leading to LOH in a fraction of the cells. We conﬁrmed the
allele ratio abnormality in NA18573 by testing six of the SNPs
in the region by an independent methodology, the RFLP.
35 Using data from the six SNPs we obtained an average allele
ratio of 0.52 while real time PCR results using Taqman assays
were consistent with a copy number of 2 validating our obser-
vations (Table 2). In one sample NA12874, all the SNPs in
 97 Mb on chromosome 1 were homozygous reﬂecting either
40 true identity by descent for the two homologs or a somatic
recombination event.
Abnormalities in the cancer cell lines
Four cancer cell lines as well as a matched normal/cancer cell
line pair were studied (Table 1). Several abnormalities were
45 identiﬁedincludingdeletions,ampliﬁcationsandLOHwithout
copy number changes.
Four homozygous deletions were found in the cell line
HCC1395. All were tested and conﬁrmed using real-time
PCR (Table 2). A breakpoint of one of these deletions is
50 mapped to  20 kb region (Figure 6). The minimum back-
ground and cross hybridization in the assay can be seen in
the lack of signal from regions with homozygous deletions in
contrast to other described technologies (4).
Several ampliﬁcations were detected in the cell line
55 UACC812 (Figure 7). This cell line has been assessed previ-
ously and sites of ampliﬁcation to >7 copies reported (10). We
detect four ampliﬁcation sites on chromosome 13; these sites
overlap well with the previous report (10). In addition we
found several previously unreported ampliﬁcation sites on
60 chromosome 17. We used real-time PCR to conﬁrm the valid-
ity of the chromosome 17 ﬁndings (Table 2). In both cases we
have underestimated the copy number in these ampliﬁcations
possibly owing to feature saturation in a manner consistent
with other techniques (10). Our copy number estimation of the
65 ampliﬁcation sites in chromosome 13 was quite similar to that
reported using direct hybridization to an oligonucleotide array
(10), while our results on chromosome 17 yielded more accur-
ate measurements of copy number.
Utilization of allele information
70 LOH events with no copy number change can be readily
detected using polymorphic markers. LOH is sometimes lim-
ited to a single chromosomal arm (Figure8A), or it can include
a large fraction of the genome as is observed in the cell line
HCC1937 CRL2336 (data not shown).
75 Except for techniques looking at cells directly, copy number
determination is generally made by the relative copy number
of a marker to the rest of the genome. With an assumption of a
modal chromosome copy number of 2, absolute copy numbers
are assigned for all markers. Allele ratio information is helpful
80 in determining the absolute copy number in samples with
modal chromosome copy number distinct from 2. Example
of the interpretation of allele and copy number information to
determine the absolute copy number is shown in Figure 8B for
the cell line MDA-MB-175-VII.
85 FFPE samples utilization
Archival FFPE blocks are a rich source of clinical specimens,
but their nucleic acids are often degraded creating a challenge
for molecular analysis. The intact stretch of DNA that MIP
probes require for proper hybridization is only  40 bp, and
90 therefore we hypothesized that MIP may generate good results
from these samples. In a proof of principle experiment we
assessed the copy number determination of three FFPE sam-
ples. We assessed three FFPE samples from different normal
tissues with varying degrees of degradation (Figure 9A).
Table 2. Summary of real-time PCR data
Sample Chromosome Position
(Mb)
Method Copy number
(real time PCR)
Copy number
(MIP)
NA19193 12 31.3 Taqman 2.8 ± 0.69
a 2.4
NA18573 15 71.6 Taqman 1.86 ± 0.31
b 2
HCC1395 2 114.3 SYBR 0.09 ± 0.006
c 0.06
HCC1395 6 105.6 SYBR 0.12 ± 0.008 0.06
HCC1395 5 107.3 Taqman 0.05 ± 0.016 0.05
HCC1395 13 59.2 Taqman 0.05 ± 0.012 0.02
UACC-812 17 35.1 SYBR 42.3 ± 1.4
c 15.1
UACC-812 17 12.5 SYBR 7.7 ± 0.16 4.4
UACC-812 17 44.2 SYBR 8.4 ± 0.032 4.7
UACC-812 17 3.4 SYBR 9.4 ± 1.4 3.4
UACC-812 17 24.4 SYBR 8.0 ± 0.44
c 5.6
All the real-time PCR was done in duplicates except when indicated.
aEstimated from 40 replicates. Therefore the estimated standard error of the
average is 0.11.
bEstimated from 6 replicates. Therefore the estimated standard error of the
average is 0.13.
cDetermined by average of two duplicates from two different real-time PCR
loci totaling four reactions.
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similar to a cell line sample run at the same time.
We then assessed one FFPE tumor/normal pair of samples.
The tumor sample showed large-scale aberrations evident by
5 abnormalities in copy number and allele ratio. We discern that
most of the chromosomes in this tumor have six copies
(Figure 9C). In contrast the normal sample had a similar pat-
tern to other normal FFPE samples (data not shown).
Figure 6. Detection of a homozygous deletion. The X-axis shows the chromosomal position in a region of chromosome 5, and the Y-axis shows the copy number
inthecelllineHCC1395.Threemarkers(ingreybox)showingminimalsignalindicatethepresenceofahomozygousdeletion.Ononeside,thedeletionbreakpointis
mapped to a 20 kb segment.
Figure 7. Detectionofamplifications.Thisis a genomiccopynumberviewofthecancer celllineUACC812.Eachchromosomeis labeledand codedwitha unique
color. The use ofthe fullset of 18180 markers withvalid genotypingdata showedthe amplification siteswith more clarity. The X-axis shows the 18180 markers in
their genomic order, and the Y-axis shows the copy number. Several amplifications are seen with the most dramatic on chromosomes 13 and 17.
e183 Nucleic Acids Research, 2005, Vol. 33, No. 21 PAGE 10 OF 14Figure8.Integratedcopynumberandalleleratioincancercelllines.(A)ThisisagenomiccopynumberandalleleratioviewofA2058cellline.Eachchromosomeis
labeled and coded with a unique color. The X-axis shows the best 10101 markers in their genomic order, and the Y-axis shows the smoothed copy number (upper
panel)andsmoothedalleleratio(lowerpanel).Thegrayarrowpointstoasectionofchromosome11thathasundergoneLOH(alleleratioof0)withnocopynumber
change(copynumberof2).Theredarrowpointstoasectionofchromosome1withanalleleratioof0.5,consistentwiththepresenceofthreecopies.Integratedcopy
numberandalleleratioinformationareconsistentwiththepresenceofthreecopiesofsectionsofchromosomes5,6,7,8and13.(B)Thisisagenomiccopynumber
andalleleratioviewofMDA-MB-175-VIIcellline.Eachchromosomeislabeledandcodedwithauniquecoloranditsnumberisnotedabove.TheX-axisshowsthe
markers in the genomic order, and the Y-axis shows the smoothed copy number (upper panel) and smoothed allele ratio (lower panel). The Y-axis shows the copy
numberautomaticallygeneratedvalueassumingamodalchromosomecopynumberof2(black)orbyinterpretationofcopynumberandalleleratio(blue).Whenthe
modal number of chromosomes in a cell is not 2, interpretation of both copy number and allele ratio is necessary is helpful in determining the absolute number of
chromosomalcopies.Thisisanexampleofsuchinterpretationofthiscombineddata.Thereareseveralchromosomalregionswithanalleleratioof0.5indicatingthe
presenceofthreeorthemultipleofthreechromosomes.Specificallyboththeredarrowlabeled2pointingtoasectioninchromosome1andthebluearrowpointingto
chromosome 2 have allele ratio of 0.5. However the corresponding copy numbers are quite different between the two chromosomes. We conclude that the copy
numberforthesectiononchromosome1andchromosome2aresixandthreecopies,respectively.Similarly,chromosomes6,9andthedistalpartofchromosome8
havealleleratioof0.5.Giventhecopynumberdifferencesweconcludethattheformertwohavethreecopies,whilethelatterhassixcopies.Chromosome3(yellow)
hasanalleleratioof 1andaslightlyhighercopynumberthanchromosome2.Thisisconsistentwithfourchromosome2copies—twoforeachofthetwohomologs.
Thesameistrueforotherchromosomes,e.g.chromosomes6and13.Chromosome14hasaslightlyhighercopynumberthanchromosome13andhasanalleleratio
0.6–0.7. This is consistent with five copies of chromosome 14—three copies of one homolog and two copies of the other. Finally there are regions of LOH as
manifestedbytheproximalsegmentofchromosome1.Thecopynumberofthissegmentisalmosthalfthatdeterminedforchromosome3,andisthereforeconsistent
with carrying two copies of one homolog and zero for the other. With this integrated information about copy number and allele ratio we conclude this cell line has
large chromosomal segments with copy number ranging from two to six copies. The blue numbers next to the copy number axis values are those resulting from
the above interpretation of the combined copy number and allele ratio views. These conclusions are consistent with previous FISH data that characterized this cell
line as having 84 chromosomes and most chromosomes present in three or four copies (25) (http://www.atcc.org).
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Large-scale assessment of clinical material for genomic
deletions and duplications imposes several requirements on
the technology. Most fundamentally it needs to allow the
5 scalable testing thousands of loci at the same time to cover
the entire genome while being able to assess hundreds or
thousands of samples at high throughput. Customization
and extraction of the allele information as well as ability
to study FFPE samples are additional important features in
10 a technology. We have demonstrated these features in this
proof of principle application of the highly multiplexed
MIP technology to copy number determination.
We have shown the false positive and negative metrics for
single marker detection of single copy number changes using
15 MIP. These metrics are favorable when compared with pre-
viously published reports (20). We have also shown that we
can choose a set of markers with better performance suggest-
ing this can be improved by iteration if desired.
The sensitivity and resolution can be traded off against each
20 other by using information from multiple markers. The use of
multiple markers makes it easier to detect copy number
changes at the expense of missing smaller changes covering
only one marker. For example we have identiﬁed in this work
large mosaic genomic abnormalities that would not have been
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genome is not uniform. For example ﬁne resolution in genes
that have a higher a priori probability to undergo some form of
rearrangement is more important than in a genomic region
5 lacking genes. Being able to interrogate genomic sites of inter-
est at the density of choice is an important advantage of our
technique. Using BAC arrays one cannot obtain much greater
resolution than 100 kb because of the size of the BAC clones.
In addition if a speciﬁc BAC does not perform well there is no
10 recourse but to eliminate the 100 kb it covers from the ana-
lysis. Oligonucleotide CGH technologies may theoretically be
customizable to assess any genomic region with great density.
However reduced representation techniques are limited to the
studyofthoserepresentedgenomic regions. Moreimportantly,
15 poor hybridization uniformity and cross hybridization greatly
limits the number of possible oligonucleotides that have good
performance. Processes of in silico and in vitro screening are
required to obtain acceptable loci in these cases, limiting the
reach and ﬂexibility of these techniques. However MIP has
20 been developed as an efﬁcient method for custom SNP geno-
typing (15), and is therefore suitable to assess copy number at
high density in regions of interest. We believe the quantiﬁca-
tion performance described in this report can be replicated
with other sets of SNPs or non-polymorphic sites because
25 we have applied only limited ﬁltering in building this panel.
We have limited ourselves to the analysis of SNPs even
though relaxing this restriction improves the chances of
designing better probes for copy number determination
because of the dramatic increase of the number of sequences
30 that can be designed. We believe this feature is outweighed by
the advantages of obtaining allele information. These include
the ability to detect LOH events that are not accompanied
by copy number changes as well as the determination of
the absolute copy number of a genomic segment in a sample
35 as we have demonstrated. In addition the collection of allele
information identiﬁes alleles that are preferentially deleted or
duplicated in a set of different samples (21,22). Such identi-
ﬁcation can allow the deﬁnition of the critical gene in a large
genomic deletion or duplication. LOH events have been stud-
40 ied previously using high-throughput technologies. However,
to our knowledge the assessment of allele ratio and distin-
guishing, e.g. a 2:1 from 1:1 ratio using high-throughput tech-
nologies has not been shown previously.
In addition to being able to detect various types of genomic
45 abnormalities, it is critical to be capable of assessing the vari-
ety of available sample types. Most cancer tissue samples are
available as FFPE. DNA from these samples is known to be
degraded to different degrees. An important feature of our
technology is that we use probes that have a genomic footprint
50 of  40 bp, in contrast to the reduced representation methods
amplifying regions that are several hundred base pairs to >1k b
in size. Therefore we expect our technology to accommodate
degraded DNA. Indeed, we presented a proof of principle for
the utilization of these samples in the MIP assay. This has not
55 been shown previously for the other oligonucleotide CGH
techniques.
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Figure 9. AnalysisofFFPEsamples.(A)WeshowanagarosegelpictureofDNApurifiedfromastandardbloodcontrolsampleandthreeFFPEsamplesfornormal
brain, colon and liver. The integrity of DNA in the three samples varies. (B) A genomic copy number view of the three normal FFPE samples shown in (A) and
NA12156,anormalcelllinecontrolsample.Eachoftheautosomesislabeledandshownwithauniquecolor.TheX-axisshowsthemarkersinthegenomicorder.The
Y-axisshowsthesmoothedcopynumberusingamovingwindowofsevenmarkers.ThepanelsfromtoptobottomshowresultsofthenormalNA12156andthethree
FFPE samples from normal brain, colon and liver. The performance of all three FFPE samples is quite similar to the normal control cell line. (C) A genomic copy
number view of a FFPE liver tumor sample. Each of the autosomes is labeled and shown with a unique color. In both panels the X-axis shows the markers in the
genomic order. The Y-axis shows the smoothed copy number using a moving window of seven markers (upper panel) and smoothed allele ratio using a moving
window of seven markers (lower panel). The blue arrow points to a region of chromosome 2 with an allele ratio of 0.35, consistent with 3:1 ratio between the two
alleles indicating the presence of four copies. There are other genomic segments like regions of chromosome 6 (denoted by bright blue/green arrow) that have the
same allele ratio and are probable to have four copies of the chromosomes. Most other chromosomes have an allele ratio close to 1 indicating an even number of
chromosomes.Thecopynumberofthesechromosomesmustbehigherthan4asis evidentfromthecopynumberdata,anditis mostprobably6giventhemeasured
difference in copy number with those regions with four copies. The blue numbers next to the copy number axis values are based on the interpretation of both the
copy number and allele ratio views.
PAGE 13 OF 14 Nucleic Acids Research, 2005, Vol. 33, No. 21 e183To use MIP in large scale for copy number analysis, several
tasks need to be accomplished. First, there needs to be extens-
ive assessment of systematic error between experiments done
in different days using distinct reagent sets. If no such error
5 exists, reference samples need not be run with each set of test
samples studied. More importantly, reduction of the current
MIPrequirementof2mgofDNA isnecessary.Wehave shown
the ability to utilize f29 whole genome ampliﬁed DNA for
copy number analysis with MIP (data not shown). However
10 because many types of samples are difﬁcult to amplify the
ability to use f29 ampliﬁed DNA is not a substitute for being
able to assess small amounts of genomic DNA directly.
The ability to interrogate the wide variety of clinical sam-
ples to obtain high-resolution allele copy number information
15 in the regions of interest will be important in oncology
research. Integrating this data with other genomic information
such as somatic point mutation scanning, RNA expression
and/or methylation analysis is probable to shed light on the
process of tumorgenesis, identify targets for pharmaceutical
20 response and discover biomarkers that predict patients’ pro-
gnosis and response to medications. In addition the study of
copy number in germline DNA may prove useful in a wide
variety of other phenotypes as suggested by the presence of
many copy number polymorphisms associated with human
25 disease (23,24).
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